Amphastar Pharmaceuticals, Inc. AMPH

Rank #174 · Nasdaq · $1.2B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

74.4

P/E

8.9

P/B

2.31

ROE

26.0%

Op. Margin

30.6%

Debt Ratio

160%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★★☆

Good

P/E 8.9x, P/B 2.31x. Ranks in the top 24% of the universe.

Profitability ★★★★☆

Excellent

ROE 26.0%. Ranks in the top 12% of the universe.

Safety ★★☆☆☆

Average

Debt ratio 160%. Ranks in the top 55% of the universe.

Growth ★★★★☆

Excellent

Revenue growth of 29.1% year over year. Ranks in the top 12% of the universe.

Valuation is the relative strength · Safety is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	–	$0.0B	$0.0B	$0.2B	–	42
2015	–	$0.0B	$0.0B	$0.2B	–	46
2016	–	$-0.0B	$-0.0B	$0.3B	–	38
2017	–	$-0.0B	$-0.0B	$0.3B	–	35
2018	$0.3B	$0.0B	$0.0B	$0.3B	6.0	35
2019	$0.2B	$-0.0B	$0.0B	$0.3B	-0.5	45
2020	$0.3B	$-0.0B	$-0.0B	$0.4B	-2.9	42
2021	$0.3B	$-0.0B	$0.0B	$0.4B	-0.0	45
2022	$0.3B	$0.0B	$0.0B	$0.4B	3.1	53
2023	$0.4B	$0.1B	$0.1B	$0.4B	16.0	48
2024	$0.5B	$0.1B	$0.1B	$0.4B	21.5	196
2025	$0.6B	$0.2B	$0.1B	$0.5B	30.6	160